The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the Shc phosphotyrosine-binding domain

Endocrinology

Volumn 140, Issue 9, 1999, Pages 3992-3998

  Ishiguro, Yoshihiro ^a   Iwashita, Toshihide ^a   Murakami, Hideki ^a   Asai, Naoya ^a   Iida, Ken Ichi ^a   Goto, Hidemi ^a   Hayakawa, Tetsuo ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GLUTATHIONE TRANSFERASE; PHOSPHOTYROSINE; TYROSINE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CONSENSUS SEQUENCE; GENE MUTATION; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MULTIPLE ENDOCRINE NEOPLASIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTO ONCOGENE;

EID: 0033305444     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.9.7003     Document Type: Article

References (40)

1. Binding affinities of tyrosine-phosphorylated peptides to the COOH-terminal SH2 and NH2-terminal phosphotyrosine binding domains of Shc
2. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
3. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases
4. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation
5. Specificity of the PTB domain of Shc for b turn-forming pentapeptide motifs aminoterminal to phosphotyrosine
6. Binding of Shc to the NPXY motif is mediated by its N-terminal domain
7. Identification of residues that control specific binding of the Shc phosphotyrosine-binding domain to phosphotyrosine sites
8. GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF
9. Characterization of a multicomponent receptor for GDNF
10. A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor
11. Neurturin, a relative of glial-cell-line-derived neurotrophic factor
12. Calcium-dependent Ret activation by GDNF and neuturin
13. Persephin, a novel neurotrophic factor related to GDNF, and neurturin
14. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex
15. Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations
16. RET mutations in human disease
17. The MEN-2 syndromes and the role of the ret proto-oncogene
18. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
19. Mechanism of activation of the ret protooncogene by multiple endocrine neoplasia 2A mutations
20. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation
21. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype
22. Loss of function effect of RET mutations causing Hirschsprung disease
23. Molecular heterogeneity of RET loss of function in Hirschsprung's disease
24. Mechanism of Ret dysfunction by Hirschsprung mutations affecting its extracellular domain
25. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease
26. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins
27. Identification of Shc docking site on Ret tyrosine kinase
28. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2
29. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2
30. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN2A, and MEN2B mutations
31. Identification of the ret protooncogene products in neuroblastoma and leukemia cells
32. Biological, and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma
33. Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: A novel C-terminus for RET
34. Expression of RET 3' splicing variants during human kidney development
35. The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor
36. Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain
37. Affinity, specificity, and kinetics of the interaction of the SHC phosphotyrosine binding domain with asparagine-X-X-phosphotyrosine motifs of growth factor receptors
38. The role of the NPXY motif in the insulin receptor in tyrosine phosphorylation of insulin receptor substrate-1 and Shc
39. Endothelin receptor-mediated signaling in Hirschsprung's disease
40. Distinct biological properties of two RET isoforms activated by MEN2A and MEN2B mutations